LONGITUDINAL CAPACITY REPORT
D. CHEN · MRN 40402-CGenerated Jul 16, 2026 · UnDun Health
PATIENT CAPACITY REVIEW
David Chen
58 yrs · Male · TRT · Reporting period Apr–Jul 2026 (12 weeks)
Patient view ↗
COMPOSITE · vs BASELINE
+1.8%
▲ Improving · watch
UNDUN INTELLIGENCE · SUMMARY
Composite is +1.8%, led by cognitive +6.4%, but the gain may not be functional. It began only after a sedative sleep aid started in week 3, while HRV fell −12% in parallel. Consider a pharmacological effect on the assessment.
FLAGGED THIS CYCLE
COGNITIVE +6.4% HRV −12%
RECOMMENDED ACTION
Message the patient; reassess the sleep aid and retest cognition off-medication before crediting the protocol.
Concise view. Switch to Standard for domains and trajectory, or Comprehensive for the full workup: heat map, aging projection, intervention impact and labs.
Capacity by domain
| DOMAIN | vs BASELINE | 12-WK TREND | STATUS |
|---|---|---|---|
| Cognitive | +6.4% | improving | MEANINGFUL |
| Vitality | +1.0% | holding | STABLE |
| Locomotion | +0.8% | holding | STABLE |
| Psychological | +0.6% | holding | STABLE |
| Sensory | 0.0% | stable | STABLE |
Composite is the mean of the five domain scores, each expressed as percent from personal baseline.
Composite trajectory
Composite capacity, percent from personal baseline. Cognitive-led rise begins after the week-3 sedative, as HRV declines.
INTERVENTION TIMELINE
TRT
Sedative
Suggested care plan
MONITOR
UNDUN INTELLIGENCE · DECISION SUPPORT
Objective: Confirm the cognitive gain is functional, not a medication artifact.
MEDICATION
Reassess the sleep aid with the prescriber; consider taper.
TESTING
Retest cognition off medication after adequate washout.
MONITORING
Track HRV recovery weekly; expect rebound if medication-driven.
LABS
Order hematocrit and blood pressure at next draw (TRT monitoring).
FOLLOW-UP
Re-evaluate in 4 weeks before crediting the protocol.
Draft plan generated by UnDun Intelligence. Requires clinician review and sign-off before it takes effect.
Signed Date
Wearable vitals
HRV (rMSSD)−12%
Resting heart raterising
Deep sleep+18%
Hematocrit52%
Data coverage90%
Active interventions
TRTACTIVE
Adherence 98%. Watch hematocrit and blood pressure per protocol.
Sedative sleep aidSTARTED WK 3
Timing coincides with the cognitive rise and HRV decline.
Week-by-week detail
W1
W2
W3
W4
Composite
+0.8
+1.3
+1.5
+1.8
Cognitive
+2.9
+4.6
+5.5
+6.4
Vitality
+0.5
+0.7
+0.9
+1.0
Locomotion
+0.4
+0.6
+0.7
+0.8
Psychological
+0.3
+0.4
+0.5
+0.6
Sensory
0.0
0.0
0.0
0.0
Each domain by week, percent from baseline. Composite is the row mean.
Sleep & recovery
Avg sleep duration7.3 h
In range
Sleep consistency76%
Good
Deep sleep+18%
Since sedative — watch
REM sleep1.4 h
20% of night
Resting HRRising
Watch on TRT
HRV (rMSSD)−12%
Declining
Body composition & activity
Weight−0.6%
Stable
Lean mass+1.8%
Holding
Body fat−1.4%
Down
Hematocrit52%
High — monitor
Avg daily steps7,800
Good
Active days22 / 30
Consistent
Measured intervention effect
Composite capacity in the four weeks before versus after each intervention started, isolating its measured effect.
| INTERVENTION | 4-WK PRE | 4-WK POST | Δ |
|---|---|---|---|
| TRT | +0.3% | +1.2% | +0.9% |
| Sedative sleep aid | +1.2% | +2.1% | +0.9% |
Projected intervention impact
Estimated effect of each lever at target adherence, with the projected years of function preserved. Illustrative, model-based projections.
VITALITY · METABOLIC
+5%
above baseline
3 yrs
delayed symptoms
TRT (verified response)
Restored testosterone+4%
Body composition+1%
COGNITIVE · SLEEP
+4%
above baseline
2 yrs
delayed symptoms
Sleep architecture, off sedative
Non-pharmacological sleep+3%
HRV recovery+1%
Domain heat map
On track
Watch
Concerning
Cognitive
Vitality
Locomotion
Psychological
Sensory
12 wk agonow
Weekly capacity status by domain, relative to personal baseline. Amber marks drift; red marks a crossed threshold.
Aging trajectory projection
YOUR TRAJECTORY
REFERENCE AGING
SYMPTOM THRESHOLD
Trajectory stays above threshold to age 85 if the gain is genuine; re-assess once confirmed off-medication.
Recent labs & biomarkers
| MARKER | VALUE | REF RANGE | FLAG |
|---|---|---|---|
| Hematocrit | 52% | 40–50 | HIGH |
| Total testosterone | 780 ng/dL | 300–1000 | — |
| PSA | 1.2 ng/mL | <4.0 | — |
| hs-CRP | 0.9 mg/L | <1.0 | — |
| ApoB | 85 mg/dL | <90 | — |
| Estradiol | 34 pg/mL | 10–40 | — |
Most recent panel on file. Flags are relative to standard reference ranges, not personalized targets.
Reviewing clinician: Dr. A. Okafor · UnDun Health. This report summarizes passively collected wearable and body-composition data interpreted against the patient's own baseline. UnDun Intelligence findings are decision-support hypotheses, not diagnoses, and do not replace clinical judgment.